Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactoplantibacillus plantarum + levilactobacillus brevis
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactoplantibacillus plantarum + Levilactobacillus brevis is a probiotic combination product consisting of two specific bacterial strains: *Lactoplantibacillus plantarum* KABP-051 (CECT 7481) and *Levilactobacillus brevis* KABP-052 (CECT 7480). Developed by AB-Biotics, this live biotherapeutic product is designed to colonize the oral cavity and exert antimicrobial activity against key periodontopathogens, including *Porphyromonas gingivalis*, *Treponema denticola*, and *Fusobacterium nucleatum*. The combination works through competitive exclusion and the production of antimicrobial substances, effectively reducing dental plaque and gingival inflammation. It has been clinically evaluated in randomized controlled trials for the management of gingivitis, the reduction of dental plaque, and the mitigation of post-operative pain following mandibular third molar extractions. The strains are selected for their low acidogenic potential and lack of transmissible antibiotic resistance genes, making them suitable for oral health applications.
- Brand names
- PerioBalanceAB-Dental
- Other names
- Lactobacillus plantarum + Lactobacillus brevisL. plantarum KABP-051 + L. brevis KABP-052Lactoplantibacillus plantarum KABP-051 + Levilactobacillus brevis KABP-052
Beyond the preview
Go deeper on lactoplantibacillus plantarum + levilactobacillus brevis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactoplantibacillus plantarum + levilactobacillus brevis.